Last 918.05 INR
Change Today -2.25 / -0.24%
Volume 58.4K
STR On Other Exchanges
Symbol
Exchange
Natl India
As of 11:35 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

strides arcolab ltd (STR) Snapshot

Open
921.00
Previous Close
920.30
Day High
926.00
Day Low
913.05
52 Week High
12/5/14 - 999.00
52 Week Low
02/26/14 - 269.28
Market Cap
54.7B
Average Volume 10 Days
364.1K
EPS TTM
--
Shares Outstanding
59.6M
EX-Date
10/16/14
P/E TM
--
Dividend
5.00
Dividend Yield
11.92%
Current Stock Chart for STRIDES ARCOLAB LTD (STR)

Related News

No related news articles were found.

strides arcolab ltd (STR) Related Businessweek News

View More BusinessWeek News

strides arcolab ltd (STR) Details

Strides Arcolab Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical products in India and internationally. The company develops generic pharmaceutical product portfolio in therapeutic segments, such as immune-suppressants, anti-virals, antibiotics, complex vitamins, and anti-lipidemics; and offers general tablets, hard and soft gelatin capsules, sachets, potent drugs, liquid filled hard gel capsules, creams, ointments, and liquids and syrups. In addition, it provides branded generic products; supplies drugs in the anti-retroviral and anti-malaria segments; and is engaged in bio generics business, as well as offers and oncology, nephrology, critical care products. The company was formerly known as Strides Pharmaceuticals Private Limited and changed its name to Strides Arcolab Limited in 1996. Strides Arcolab Limited was founded in 1990 and is headquartered in Bengaluru, India.

1,500 Employees
Last Reported Date: 08/14/14
Founded in 1990

strides arcolab ltd (STR) Top Compensated Officers

Founder, Executive Vice Chairman, Managing Di...
Total Annual Compensation: 53.9M
Compensation as of Fiscal Year 2014.

strides arcolab ltd (STR) Key Developments

Strides Arcolab Enters Licensing Agreement to Manufacture Antiretroviral TAF Treatment

Strides Arcolab has finalised a licensing agreement to manufacture and distribute a generic version of Gilead Sciences (US)'s tenofovir alafenamide (TAF) investigational antiretroviral treatment. The decision to extend non-exclusive rights to Strides Arcolab will allow the company to commercialise a low-cost generic copy of the drug in 112 developing countries as a single agent and combination medicine. As part of the agreement (viewed here) the Indian firm has also negotiated a technology transfer from Gilead Sciences. In September 2014, Gilead Sciences previously sub-licensed five other India-based manufacturers - Aurobindo, Cipla, Emcure, Hetero, and Laursus Laboratories (as well as China's Desano) - to manufacture and market the product in the same 112 low- and middle-income countries. Mylan (US) has received similar non-exclusive rights. Gilead Sciences announced positive Phase III clinical trials data for TAF in September 2014 related to the safety and efficacy of the once-daily single-tablet dose of the treatment. Clinical trials have also favourably compared TAF as a combination treatment versus Stribild (elvitegravir; seeUnited States: 25 September 2014:). The results also demonstrated non-inferiority of TAF at 10 times lower doses compared with Viread (tenofovir disoproxil fumarate) with the same active ingredient.

Strides Arcolab Announces Cessation of Mukul Sarkar as Director

Strides Arcolab Ltd. announced that EXIM Bank, Mumbai has withdrawn the nomination of Mr. Mukul Sarkar from the Directorship of the company. Accordingly, Mr. Mukul Sarkar ceases to be a Director of the company with effect from December 15, 2014.

Strides Arcolab Ltd. Receives US FDA Approval for Calcitriol Softgel Capsules

Strides Arcolab Limited announced that it has received approval from the United States Food & Drug Administration for Calcitriol Softgel Capsules, 0.25mcg and 0.5mcg. According to IMS data, the US market for generic Calcitriol Softgel Capsules is approximately USD 50 million, with only three players having approval for both the strengths of Calcitriol. The product will be manufactured at the company’s oral dosage facility at Bangalore and marketed by the company in the US Market.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STR:IN 918.05 INR -2.25

STR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,725 GBp +25.00
Endo International PLC $79.73 USD +0.58
Johnson & Johnson $102.09 USD -0.17
Merck & Co Inc $62.56 USD -0.26
Pfizer Inc $32.60 USD -0.20
View Industry Companies
 

Industry Analysis

STR

Industry Average

Valuation STR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 3.4x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STRIDES ARCOLAB LTD, please visit www.stridesarco.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.